| Identification | Back Directory | [Name]
Rabacfosadine succinate | [CAS]
1431856-99-3 | [Synonyms]
GS-9219-01
GS-9219 succinate
VDC-1101 succinate
Rabacfosadine succinate
VDC 1101 succinate VDC1101 succinate
ethyl (2S)-2-[[2-[2-amino-6-(cyclopropylamino)purin-9-yl]ethoxymethyl-[[(2S)-1-ethoxy-1-oxopropan-2-yl]amino]phosphoryl]amino]propanoate | [Molecular Formula]
C25H41N8O10P | [MOL File]
1431856-99-3.mol | [Molecular Weight]
644.62 |
| Chemical Properties | Back Directory | [InChIKey]
XLBDQSJWTNREFA-FGVWXQOBNA-N | [SMILES]
C(C(=O)O)CC(=O)O.C(N1C=NC2=C(N=C(N)N=C12)NC1CC1)COCP(=O)(N[C@@H](C)C(=O)OCC)N[C@@H](C)C(=O)OCC |&1:29,37,r| |
| Hazard Information | Back Directory | [Description]
Rabacfosadine succinate(1431856-99-3), also known as VDC-1101 or GS-9219, is a double prodrug of the nucleotide analogue 9-(2-phosphonylmethoxyethl)guanine (PMEG). It is a novel chemotherapy drug approved for the treatment of lymphoma in dogs. Rabacfosadine administered every 3 weeks is usually well tolerated and has shown significant anti-tumour activity in dogs with previously untreated medium and large cell lymphoma.
| [Uses]
Rabacfosadine succinate(1431856-99-3) is used as the acyclic nucleoside phosphonate PMEG double prodrug.
| [Mechanism of action]
Rabacfosadine succinate(1431856-99-3) targets lymphocytes and acts as an anti-tumour agent by inhibiting DNA synthesis through the inhibition of DNA polymerase.
| [Side effects]
The most common adverse reaction to Rabacfosadine succinate is gastrointestinal (anorexia/diarrhoea), which is generally resolved by supportive therapy and/or dose adjustment. Three dogs developed VCOG-CTCAE grade 5 delayed pulmonary fibrosis. |
|
|